| I-030 Martin Bergstrand A workflow for evaluating and optimizing the designs of paediatric studies Wednesday 10:20-11:50 |
| I-065 Yi-Han Chien Modelling framework to simulate phenotypic results of antiviral PROTACs Wednesday 10:20-11:50 |
| I-073 Perrine Courlet Unlocking efficiency in dose selection based on pharmacokinetic-pharmacodynamic modeling of tumor size data: Insights from Clinical Trial Simulations Wednesday 10:20-11:50 |
| I-099 Ruben Faelens Real-world data can estimate pre-exposure prophylactic drug effect in community-acquired respiratory infection trials Wednesday 10:20-11:50 |
| II-079 Simon Koele Model-informed trial design for the malaria transmission blocking antibody TB31F Wednesday 15:20-16:50 |
| II-083 Anders Kristoffersson Optimal design of a reduced sampling schedule for the characterization of prolactin dynamics in healthy male volunteers and its evaluation to the describe the pharmacodynamic effect of a prolactin antagonist in a single rising dose study Wednesday 15:20-16:50 |
| III-037 Yomna Nassar Simulation-based evaluation of combined Likelihood Ratio Test (cLRT) and Multiple Comparison Procedure (MCP) approaches to identify a dose-response relationship in the oncology setting under different study design variables Thursday 09:50-11:20 |
| III-040 Chiara Nicoḷ Simulating maximum tolerated dose-finding oncology trials using the InSilicoTrials cloud-based platform Thursday 09:50-11:20 |
| IV-078 Axel Vuorinen A comparative analysis of Bayesian dose-finding designs incorporating pharmacokinetics information Thursday 15:00-16:30 |
| IV-109 Xiao Zhang Assessment of Sample Size Allocation for A Multi-regional Phase 2 Trial: Comparison of Statistical and Dose-Exposure-Response (D-E-R) Approaches Thursday 15:00-16:30 |
